Current Report Filing (8-k)
February 26 2013 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
February 26, 2013
|
ADVENTRX Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
001-32157
|
84-1318182
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
|
|
12390 El Camino Real, Suite 150, San Diego, California
|
|
92130
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
|
|
858-552-0866
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 26, 2013, ADVENTRX Pharmaceuticals, Inc. issued a press release reviewing the platform of data and know-how that supports development of ANX-188 in multiple indications, including those outside of sickle cell disease. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
ADVENTRX Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
February 26, 2013
|
|
By:
|
|
/s/ Patrick L. Keran
|
|
|
|
|
|
|
|
|
|
|
|
Name: Patrick L. Keran
|
|
|
|
|
|
Title: President and Chief Operating Officer
|
Exhibit Index
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press release, dated February 26, 2013
|
Adventrx (AMEX:ANX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Dec 2023 to Dec 2024
